Tesamorelin vs HGH Fragment 176-191: Research Comparison
A Side-By-Side Research Comparison Of Tesamorelin And HGH Fragment 176-191 - a GHRH analog versus an HGH fragment in fat-metabolism research. This Reference Compares Mechanism, Evidence Tier, Molecular Identity, And Pharmacokinetics For Qualified Researchers. For In Vitro Laboratory Research Use Only. Not Medical Advice Or Dosing Guidance.
Side-By-Side Comparison
| Tesamorelin | HGH Fragment 176-191 | |
|---|---|---|
| Category | Muscle Growth & Performance | Muscle Growth & Performance |
| Compound Class | Synthetic GHRH analog with trans-3-hexenoic acid modification at N-terminus; FDA-approved for HIV lipodystrophy | Synthetic fragment of HGH C-terminus (residues 176-191) |
| Evidence Tier | Approved Drug | Research Compound |
| Molecular Target | GHRH receptor (GHRHR) on pituitary somatotrophs; GH/IGF-1 axis stimulation; preferential visceral fat metabolism | Beta-3 adrenergic receptors; stimulates lipolysis without GH receptor binding; no IGF-1 elevation |
| Molecular Weight | 5135.9 Da | 1817.1 Da |
| Amino Acid Sequence | hGHRH(1-44) with trans-3-hexenoyl | 16-aa C-terminal lipolytic fragment of human growth hormone (residues 176-191) |
| CAS Number | 218949-48-5 | 66004-57-7 |
| Half-Life | ~26-38 minutes | ~3 minutes |
| Studied For | HIV-associated lipodystrophy (FDA approved), Hepatic fat / NAFLD research, Cognition research in aging/HIV, GH deficiency | Lipolysis / fat loss, Adipose reduction, Visceral fat reduction, Body composition improvement |
About Tesamorelin
An FDA-approved growth-hormone-releasing hormone analog used to reduce visceral fat in HIV-associated lipodystrophy; banned in sport.
Read The Full Tesamorelin MonographAbout HGH Fragment 176-191
A growth-hormone fragment marketed for fat loss; human efficacy is unproven and it is banned in sport.
Read The Full HGH Fragment 176-191 MonographKey Differences
- Evidence tier differs: Tesamorelin is classified as Approved Drug; HGH Fragment 176-191 is classified as Research Compound.
- Reported half-life differs: Tesamorelin at ~26-38 minutes versus HGH Fragment 176-191 at ~3 minutes.
- Primary molecular target differs: Tesamorelin acts on GHRH receptor (GHRHR) on pituitary somatotrophs; GH/IGF-1 axis stimulation; preferential visceral fat metabolism; HGH Fragment 176-191 acts on Beta-3 adrenergic receptors; stimulates lipolysis without GH receptor binding; no IGF-1 elevation.
Continue Researching
Tesamorelin · HGH Fragment 176-191 · Compare Tool · Research Library
This Comparison Is Provided For In Vitro Laboratory Research Use Only. Not For Human Consumption, Diagnosis, Or Treatment. See The Full Research Disclaimer.